Cipla’s New Bet: Expanding into Weight-Loss Care

Cipla has entered a landmark partnership with US-based Eli Lilly to sell its blockbuster weight-loss and diabetes drug, tirzepatide, in India under the brand name Yurpeak. The drug, already available as Lilly’s Mounjaro, will now reach more patients through Cipla’s vast distribution network, especially beyond major cities. Yurpeak, a once-weekly injectable therapy, will be priced the same as Mounjaro at around ₹3,500 for the 2.5 mg dose and ₹4,375 for the 5 mg version, offering a more affordable option compared with rival drug Wegovy. This tie-up marks Cipla’s formal entry into obesity management — one of the fastest-growing therapeutic areas globally. Tirzepatide is a dual-action drug that helps manage both type 2 diabetes and chronic obesity, conditions that affect over 100 million Indians. The company sees this partnership as a natural extension of its chronic care portfolio that includes respiratory, cardiac, and diabetic treatments. Cipla’s scale and strong domestic distribution can make Yurpeak widely accessible, potentially capturing a large patient base in both urban and semi-urban markets. For Cipla’s shareholders, this is a value-accretive step. The deal involves no manufacturing risk, as Lilly will continue production while Cipla focuses on marketing and reach. It gives Cipla immediate exposure to a premium therapy market without heavy R&D spending. However, pricing parity with Mounjaro limits margin upside, and competition from generic semaglutide once patents expire in 2026 could pressure growth. Still, the alliance strengthens Cipla’s position in high-value chronic therapies and signals its intent to diversify beyond conventional generics. If uptake remains strong, Yurpeak could become a long-term earnings catalyst and reinforce shareholder confidence.